At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 434 target
Drug / intervention
CM518D1 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Phase I/II Clinical Study to Evaluate CM518D1 in the Treatment of Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating CM518D1 for Advanced Solid Tumors. Currently recruiting, targeting 434 participants across 1 site.
Detailed Summary
This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20262027202820292030
First PostedJun 2025
Enrollment StartJun 2025
TodayJul 2026
Primary CompletionDec 2028
Study CompletionDec 2029
First PostedJun 13, 2025
Enrollment StartJun 27, 2025
Primary CompletionDec 31, 2028
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 1.1 years agoPrimary completion in 2.5 years
Arms & Interventions
Phase I dose escalationexperimental
Biological: CM518D1
Phase I dose expansionexperimental
Biological: CM518D1
Phase IIexperimental
Biological: CM518D1
Interventions
CM518D1biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
CM518D1biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
CM518D1biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.